Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos; Iason Psilopatis; Anna Garmpi; Dimitrios Dimitroulis; Konstantinos Nikolettos; Kleio Vrettou; Panagiotis Sarantis; Evangelos Koustas; Gregory Kouraklis; Efstathios A Antoniou; Michail V Karamouzis; Nikolaos Nikolettos; Panagiotis Tsikouras; Georgios Marinos; Emmanouil Kontomanolis; Konstantinos Kontzoglou; Nikolaos Garmpis

doi:10.3390/cancers16010209

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Cancers (Basel). 2024 Jan 1;16(1):209. doi: 10.3390/cancers16010209.

Authors

Christos Damaskos^{1

2}, Iason Psilopatis³, Anna Garmpi⁴, Dimitrios Dimitroulis⁵, Konstantinos Nikolettos⁶, Kleio Vrettou⁷, Panagiotis Sarantis⁸, Evangelos Koustas⁸, Gregory Kouraklis⁹, Efstathios A Antoniou^{2

10}, Michail V Karamouzis⁸, Nikolaos Nikolettos⁶, Panagiotis Tsikouras⁶, Georgios Marinos¹¹, Emmanouil Kontomanolis⁶, Konstantinos Kontzoglou^{2

5}, Nikolaos Garmpis^{2

10}

Affiliations

¹ Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece.
² N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
³ Department of Obstetrics and Gynecology, University Erlangen, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
⁴ First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁵ Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁶ Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
⁷ Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece.
⁸ Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁹ Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
¹⁰ Department of General Surgery and HPB Surgery of Adults and Children, Hygeia Hospital, 15123 Athens, Greece.
¹¹ Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Abstract

Background/aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.

Materials and methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.

Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.

Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Keywords: HDAC; breast; cancer; clinicopathological; deacetylase; histone; negative; triple.

Grants and funding

This research received no external funding.